Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Transfusions

Clinical trial NCT07738510 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07738510
Sponsor: Halia Therapeutics, Inc.
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Myelodysplastic Syndromes Anemia

Start date: 2026-10-01
Primary completion: 2028-10-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.